Ruxolitinib

Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.

Price Not Available 25mg Ruxolitinib Supplier Page
Trivial name INCB018424
Catalog Number S1378
Molecular Formula C17H18N6
CAS# 941678-49-5
Inchi InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
Inchi Key HFNKQEVNSGCOJV-OAHLLOKOSA-N
SMILES C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
Size 25mg
Supplier Page http://www.selleckchem.com/products/INCB18424.html
Additional Information https://file.selleck.cn/downloads/struct/s1378-ruxolitinib-incb018424-chemical-structure.png